FIELD: chemistry; medicine.
SUBSTANCE: invention can be used in production of preparations for treatment of pre-diabetic states, type 2 diabetes and glucose tolerance disturbances. Novel peptides, demonstrating properties of selective receptor VPAC2 agonists, in particular ability to stimulate insulin synthesis and its release from β-cells of pancreas by glucose-depending method, as well as following reduction of glucose level in plasma.
EFFECT: increased efficiency of action and stability in comparison with natural peptides, possibility of their successful application in treatment of diseases.
14 cl, 18 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGONISTS OF HYPOPHYSIS ADENYLATE CYCLASE PEPTIDE-ACTIVATOR RECEPTOR-3(R3)(PACAP) AND METHODS FOR THEIR PHARMACOLOGICAL USING | 2000 |
|
RU2269354C2 |
| MODIFIED VASOACTIVE INTESTINAL PEPTIDES | 2010 |
|
RU2589255C2 |
| NEW APPLICATION OF LIVER X RECEPTOR AGONISTS | 2006 |
|
RU2417078C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
| ACYLATED GLUCAGON ANALOGUE, USE THEREOF AND METHODS OF PRODUCING | 2016 |
|
RU2735762C2 |
| APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 |
|
RU2566264C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| METHOD OF TREATING IL-1BETA-DEPENDENT DISEASES | 2007 |
|
RU2554747C9 |
| HOST CELLS AND WAYS TO USE | 2014 |
|
RU2663587C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
